2022
- Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC studyTunesi S, Le Dû D, Gualano G et al. Journal of Infection 2022; https://doi.org/10.1016/j.jinf.2022.03.004
Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. Margineanu I, Rustage K, Noori T, et al. Euro Surveill. 2022;27(12):pii=2002070. https://doi.org/10.2807/1560-7917.ES.2022.27.12.2002070
Rifapentine access in Europe: growing concerns over key tuberculosis treatment componentGuglielmetti L, Günther G, Leu C, et al. Eur Respir J 2022; DOI: 10.1183/13993003.00388-2022
2020
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary.Daley C L, Iaccarino J M, Lange C et al. Clin Infect Dis. 2020; 71: e1-e36. doi: 10.1093/cid/ciaa241.
- Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? Méchaï F, Cordel H, Guglielmetti L et al. Front Public Health. 2020; 8: 443. doi: 10.3389/fpubh.2020.00443.
- Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Ong CWM, Migliori GB, Raviglione M et al. Eur Respir J. 2020; 56:2001727. doi: 10.1183/13993003.01727-2020.
2017
ESGMYC conceived a thematic section on multidrug and extensively drug-resistant tuberculosis published in CMI, 2017, Volume 23
This section included the following reviews: Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis by Dheda et al., Multidrug-resistant tuberculosis and migration to Europe by Hargreaves et al., Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases by Fox et al., Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives by Schön et al., Whole genome sequencing for M/XDR tuberculosis surveillance and for resistance testing by Walker et al.
2016
Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Andre et al., Int J Tuberc Lung Dis. 2016; 20(8):999-1003
The use of new diagnostic tests has increased dramatically in the laboratories of developing countries and in decentralised point-of-care facilities. Self-contained molecular diagnostic devices have been successfully deployed to detect tuberculosis (TB) in very basic clinical facilities. However, the introduction of an improved TB diagnostic tool is not sufficient to assure improved outcomes for patients, as the details of implementation within existing health delivery systems have a critical influence on impact. Diagnostic e-health solutions have the potential to help maximise patient and public health impact following the introduction of a particular technology. In this opinion paper, authors discussed lessons learned from the global scale-up of the first generation of easy-to-connect diagnostic tools and the pathway to tapping the potential of connectivity in the field of TB diagnostics.